• Acrivon flagged new preclinical combination data for lead cancer drugs ACR-368 and ACR-2316, positioning the results as support for future frontline development strategies.
• Findings will be presented at AACR 2026 in San Diego across April 19-20.
• ACR-368 showed synergistic anti-tumor activity in studies pairing it with PD-L1 blockade, supporting a potential immunotherapy combination path.
• Separate data indicated ACR-2316 combined with anti-PD-L1 drove complete tumor regression in models, with durable immune memory that could strengthen its clinical rationale.
• Additional results pointed to synergy between ACR-368 and Topo 1 inhibition, a common ADC payload, expanding potential partnering and combination options in ADC regimens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171600PRIMZONEFULLFEED9692218) on April 17, 2026, and is solely responsible for the information contained therein.